Non-HER2 signaling pathways activated in resistance to anti-HER2 therapy in breast cancer

• Published in: Breast cancer research and treatment Vol. 153; no. 3; pp. 493 - 505
• Main Authors: Madrid-Paredes, Adela, Cañadas-Garre, Marisa, Sánchez-Pozo, Antonio, Calleja-Hernández, Miguel Ángel
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.10.2015; Springer; Springer Nature B.V
• Subjects: Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Biomarkers, Tumor; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - mortality; Cancer; Cancer research; Cancer therapies; Carcinogens; Care and treatment; Chemotherapy; Chromosomes, Human, Pair 17 - metabolism; Drug Resistance, Neoplasm - genetics; ErbB Receptors - metabolism; Female; Gene expression; Genetic markers; Health aspects; Humans; Ligands; Medical prognosis; Medicine; Medicine & Public Health; Molecular Targeted Therapy; Oncology; Prognosis; Receptor, ErbB-2 - antagonists & inhibitors; Receptors, Somatomedin - metabolism; Review; Signal transduction; Signal Transduction - drug effects; Resistance; HER2-targeted therapies; Pharmacogenetics; Breast cancer; Lapatinib; Trastuzumab

HER2 receptor is overexpressed approximately in 20 % of human breast cancer (BC) and is a poor prognostic factor. Although therapies targeting this receptor have improved the prognosis of this cancer, up to 62 % patients treated with these drugs experiment progression during the first year of treatm...